Catalent Pharma Solutions, today announced that Ms. Humera Ahmad, Director of Product Development, Softgel – Asia-Pacific, will be presenting at the upcoming Nicholas Hall Asia-Pacific OTC Conference, to be held at the Regent Singapore Hotel, Singapore, on Oct. 20 – 21, 2016.
Somerset N.J. – October 19, 2016 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Ms. Humera Ahmad, Director of Product Development, Softgel – Asia-Pacific, will be presenting at the upcoming Nicholas Hall Asia-Pacific OTC Conference, to be held at the Regent Singapore Hotel, Singapore, on Oct. 20 – 21, 2016.
Ms. Ahmad’s presentation, on Thursday, Oct. 20 at 4:30 p.m., is entitled “Product Innovation – Your Competitive Advantage in the Market,” and will discuss a number of technical advances in softgels as a delivery platforms for both drug and consumer health products. These include plant-derived gelatin based products, serving consumers with concerns about the use of animal-derived gelatin, as well as those with dietary, religious or cultural restrictions; chewable softgels; and spherical capsules, made using a novel manufacturing technique, to be much smaller than conventional softgels. Opportunities to promote brands within the market will also be highlighted, through the use of color, size and shape options, as well as inline printing.
Ms. Ahmad joined Catalent in 2013, bringing extensive expertise in product development of both OTC and prescription products, as well as experience in managing quality, regulatory and R&D groups. In her role, she is responsible for the product development teams at Catalent’s softgel facilities in Braeside, Australia; Kakegawa, Japan; and Haining, China. Previously, she held a number of senior management roles, most recently with Probiotec Pharma for nearly 10 years, and before that, with Sigma and SmithKline Beecham. She holds a bachelor’s degree in pharmacy as well as a postgraduate diploma in industrial microbiology, both from Swinburne University, Melbourne, Australia.
Catalent has served drug development and consumer health customers in the Far East and Australasia for more than 40 years, and today has facilities in Australia, China, Japan and Singapore.
For more information on the Conference, visit: http://www.nicholashall.com/events/detail/reGeneration/ and to arrange a meeting with Ms. Ahmad at the event, contact Richard Kerns at NEPR – email@example.com.
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 9,200 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2016 generated $1.85 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com